Asked by: Mark Tami (Labour - Alyn and Deeside)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether Sir Mike Richards’ review of current cancer screening programmes and diagnostic capacity will consider the level of access to breast cancer screening for high risk groups.
Answered by Steve Brine
NHS England asked Sir Mike Richards to lead a review to improve the delivery of the screening programmes, increase uptake, learn the lessons from the recent issues around breast and cervical screening, and modernise and expand diagnostic capacity in England.
The independent review of cancer screening will include a ‘call for evidence’, however we understand from NHS England that there are no plans for a full public consultation.
The review will take account of views from partner organisations including charities and patient representative groups. Patients are also invited to engage with the review and patient groups will be consulted through engagement with partner organisations including charities and patient representative groups as part the ‘call for evidence’.
The review will assess current strengths and weaknesses in the current commissioning and delivery arrangements for the national cancer screening programmes, including breast cancer screening, in England and how best to maximise uptake across geographies and population groups.
Asked by: Mark Tami (Labour - Alyn and Deeside)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what plans his Department has to consult patients as part of Sir Mike Richards’ review of cancer screening programmes and diagnostic capacity.
Answered by Steve Brine
NHS England asked Sir Mike Richards to lead a review to improve the delivery of the screening programmes, increase uptake, learn the lessons from the recent issues around breast and cervical screening, and modernise and expand diagnostic capacity in England.
The independent review of cancer screening will include a ‘call for evidence’, however we understand from NHS England that there are no plans for a full public consultation.
The review will take account of views from partner organisations including charities and patient representative groups. Patients are also invited to engage with the review and patient groups will be consulted through engagement with partner organisations including charities and patient representative groups as part the ‘call for evidence’.
The review will assess current strengths and weaknesses in the current commissioning and delivery arrangements for the national cancer screening programmes, including breast cancer screening, in England and how best to maximise uptake across geographies and population groups.
Asked by: Mark Tami (Labour - Alyn and Deeside)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if there will be a full public consultation as part of Sir Mike Richards’ review of current cancer screening programmes and diagnostic capacity.
Answered by Steve Brine
NHS England asked Sir Mike Richards to lead a review to improve the delivery of the screening programmes, increase uptake, learn the lessons from the recent issues around breast and cervical screening, and modernise and expand diagnostic capacity in England.
The independent review of cancer screening will include a ‘call for evidence’, however we understand from NHS England that there are no plans for a full public consultation.
The review will take account of views from partner organisations including charities and patient representative groups. Patients are also invited to engage with the review and patient groups will be consulted through engagement with partner organisations including charities and patient representative groups as part the ‘call for evidence’.
The review will assess current strengths and weaknesses in the current commissioning and delivery arrangements for the national cancer screening programmes, including breast cancer screening, in England and how best to maximise uptake across geographies and population groups.